Sweden's Vimian Q1 revenue beats on acquisitions boost

Vimian AB

29/04/2026 06:53

Overview

Sweden animal health firm's Q1 revenue rose 8%, beating analyst expectations

Adjusted EBITA for Q1 grew 3% but slightly missed analyst consensus

Company completed two acquisitions, adding EUR 10 mln in annual revenues

Outlook

Vimian did not provide specific guidance for future quarters or the full year

Result Drivers

SEGMENT GROWTH - Three out of four segments delivered double-digit organic growth, ahead of the global animal health market, per CEO

INVESTMENTS IMPACT MARGINS - Adjusted EBITA margin declined due to investments in MedTech orthopedics and new market entries in Veterinary Services

Company press release: ID:nMFNq7TDc

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
EUR 116 mln
EUR 113.93 mln (6 Analysts)
Q1 Adjusted EPS
EUR 0.02
Q1 Net Income
EUR 10.10 mln
Q1 Adjusted EBITA
Slight Miss*
EUR 29.20 mln
EUR 29.25 mln (4 Analysts)
Q1 Operating Profit
EUR 21.20 mln


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Vimian Group AB is SEK37.00, about 31.4% above its April 28 closing price of SEK28.15

The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 24 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)